Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Ligand Pharm (LGND)

Ligand Pharm (LGND)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Ligand Pharm 5980 HORTON STREET SUITE 405 EMERYVILLE CA 94608 USA

P: 858-550-7500

Description:

Ligand, being a biotechnology company, focuses on developing/acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure. Ligand's Captisol formulation technology has allowed it to enter into several licensing deals and generate royalties. Captisol is a well validated chemically modified cyclodextrin that is designed to improve safety and solubility, stability, and bioavailability or lessen the volatility, irritation, smell or taste of drugs. Ligand has merged with CyDex. By this, it added an antibody-generating platform, OmniAb, to the company's portfolio. Its other technology platforms include antigen discovery platform & protein expression platform. All these technologies have created a strong platform for Ligand to seek new licenses and partnerships. Ligand has partnership agreements with leading healthcare companies like Novartis, Amgen, Merck, Pfizer, Celgene, Gilead & Lilly, etc. The company continues to buy smaller companies to increase its technology platforms.

Key Statistics

Overview:

Market Capitalization, $K 1,597,806
Enterprise Value, $K 1,256,696
Shares Outstanding, K 16,883
Annual Sales, $ 277,130 K
Annual Net Income, $ 57,140 K
Last Quarter Sales, $ 57,420 K
Last Quarter Net Income, $ -900 K
60-Month Beta 1.08
% of Insider Shareholders 10.40%
% of Institutional Shareholders 87.87%
Float, K 15,127
% Float 89.60%
Short Volume Ratio 0.75

Growth:

1-Year Return -26.57%
3-Year Return -10.33%
5-Year Return -33.84%
5-Year Revenue Growth 154.32%
5-Year Earnings Growth 4,327.27%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.34 on 08/08/22
Next Earnings Date 11/08/22
Earnings Per Share ttm 2.53
EPS Growth vs. Prev Qtr -193.33%
EPS Growth vs. Prev Year -112.07%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Most Recent Dividend 2.500 on 04/03/07
Dividend Payable Date 07/01/10
Dividend Payout Ratio 0.00%
Most Recent Split 1-6 on 11/19/10

LGND Ratios

Ratio
Price/Earnings ttm 37.10
Price/Earnings forward 72.83
Price/Earnings to Growth 4.86
Return-on-Equity % 5.49%
Return-on-Assets % 3.73%
Profit Margin % 20.62
Net Margin % -3.92
Debt/Equity 0.00
Price/Sales 5.72
Price/Cash Flow 9.84
Price/Book 1.83
Book Value/Share 47.59
Interest Coverage 3.41

LGND Dividends

Date Value
04/03/07 $2.5000
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar